Aims: To assess the genetic risk of acute respiratory distress syndrome (ARDS) and identify subgroups of patients more likely to respond to specific therapies.
Scientific rationale: Previous efforts to identify therapy for ARDS have been hampered by the heterogeneity of patients with the disease. There is need for a better way to classify subgroups of patients with ARDS too that targeted therapies can e tested. Our group has been evaluating multiple targets for treating ARDS in preclinical models. We need genetic tools to identify patients who are more likely to respond to our therapies.
Project duration: We anticipate that this project will last 36 hours.
Public health impact:The SARS-CoV-2/COVID-19 pandemic has dramatically highlighted multiple unmet need for therapy in ARDS. Most patients who died from COVID-19 had ARDS and healthcare systems across the world were overwhelmed.
